Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when SONM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company faces imminent Nasdaq delisting unless it successfully appeals by May 29, 2026, with trading suspension starting June 2.
DNA X faces Nasdaq delisting by June 2 as it raises $3M via convertible note secured by subsidiary
Filed May 27, 2026 · Period ending May 20, 2026 · ~1 min read
Key Changes
-
high
Nasdaq issued delisting notice on May 22 after company reported $983K stockholders' deficit in Q1 2026, failing minimum equity requirement. Trading suspended June 2 unless company appeals by May 29.
Item 3.01 verify on EDGAR → -
high
Company issued $3.05M convertible note to DNA Holdings Venture ($1.8M cash plus $1.25M prior note surrender), maturing Dec 2026 at 10% interest, convertible at $6/share pending stockholder approval.
Item 1.01 verify on EDGAR → -
high
Note secured by first-priority lien on DNA X LLC membership interests (company's wholly owned subsidiary), putting core operating assets at risk if company defaults on repayment.
Item 1.01 verify on EDGAR → -
high
Conversion price drops to 80% of market price during default, or to lower of original/transaction price upon change of control—both scenarios create significant dilution risk for existing shareholders.
Item 1.01 verify on EDGAR → -
medium
Proceeds restricted to working capital only; cannot be used to pay down other debt, redeem stock, or settle litigation, limiting management's financial flexibility.
Item 1.01 verify on EDGAR →
Summary
DNA X disclosed two critical developments that underscore severe financial distress. First, Nasdaq formally notified the company on May 22 that its stock will be delisted and suspended from trading on June 2 unless it appeals by May 29. The delisting stems from a $983,000 stockholders' deficit reported in Q1 2026, violating Nasdaq's $2.5 million minimum equity requirement.
The company plans to request a hearing, which will temporarily halt the delisting process, but failure to regain compliance could make shares difficult to trade and trigger defaults under existing agreements. Simultaneously, DNA X raised $3.05 million through a convertible note with DNA Holdings Venture, receiving $1.8 million in cash while retiring a prior $1.25 million obligation.
The financing comes with significant strings: the note is secured by the company's ownership stake in its primary operating subsidiary DNA X LLC, and converts to common stock at $6 per share—but drops to 80% of market price during any default. This structure protects the lender but creates substantial dilution risk for shareholders, especially given the company's precarious financial position. Retail investors should monitor whether the company files its appeal by the May 29 deadline and watch for any announcement of the hearing outcome, as delisting would severely impair liquidity and likely trigger a sharp stock price decline.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Company’s obligations under the Note are secured by a first priority lien and security interest in and to the following collateral (collectively, the “Pledged Collateral”): (i) the limited liability company membership interests owned by the Company in its wholly owned subsidiary DNA X, LLC, a Delaware limited liability company, and all dividends, cash, instruments, and other property from time to time received or distributed in respect thereof and all proceeds of any of the foregoing in whatever form.
The note is secured by a first priority lien on the Company's membership interests in its wholly owned subsidiary DNA X, LLC, along with all associated dividends, cash, and property. This security interest remains in effect until the note is fully paid. Pledging the primary operating subsidiary as collateral represents significant creditor protection and potential risk to equity holders if the Company defaults.
Added in current filing · verify on EDGAR →
The SPA requires the proceeds from the sale of the Note to be used for working capital purposes, but not for the satisfaction of any Company debt (other than the payment of trade payables in the ordinary course of business), the redemption of common stock or common stock equivalents, the settlement of any litigation, or in violation of certain antibribery and anticorruption laws specified in the Purchase Agreement.
The $1.8 million cash proceeds must be used for working capital and cannot be used to pay down other debt, redeem equity, or settle litigation. This restriction limits management's financial flexibility and suggests the lender wants to ensure funds support ongoing operations rather than addressing other obligations.
Added in current filing · verify on EDGAR →
Concurrently with the closing of the transactions contemplated by, and as a condition and inducement to the Company’s willingness to enter into, the Purchase Agreement, the Company and the Purchaser entered into an Amendment No. 1 to the Membership Interest Purchase Agreement (the “Purchase Agreement Amendment”) pursuant to which the Company and the Purchaser agreed to terminate the “Put Option” described therein, effective as of the execution of the Purchase Agreement.
As a condition of the new financing, the Company and DNA Holdings Venture terminated a previously existing "Put Option" under a prior Membership Interest Purchase Agreement. The termination of this put option removes a potential obligation or right that existed between the parties, though the specific terms of the original put are not disclosed in this filing.
Event · Item 2.03 — Creation of a Direct Financial Obligation
DNA X, Inc. disclosed creation of a direct financial obligation, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 2.03Creation of a Direct Financial Obligation or an Obligation under an Off-Balane Sheet Arrangement of a Registrant. The information set forth in Item 1.01 above is hereby incorporated by reference into this Item 2.03.
The company disclosed the creation of a direct financial obligation under Item 2.03. However, the substantive details are incorporated by reference from Item 1.01, which is not included in the provided filing excerpt. This typically indicates new debt, credit facility, or similar financial commitment.
Event · Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule
Item 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On May 22, 2026, the Company received a delisting determination letter from the Staff advising the Company that unless the Company requests a hearing before a Nasdaq Hearing Panel (the “Panel”) to appeal Nasdaq’s delisting determination by May 29, 2026, trading of the Company’s common stock will be suspended at the opening of business on June 2, 2026.
The company received formal notice from Nasdaq on May 22, 2026 that its stock will be delisted and trading suspended starting June 2, 2026 unless it appeals by May 29, 2026. The company plans to request a hearing, which will stay the delisting pending the hearing outcome.
Added in current filing · verify on EDGAR →
The Company reported stockholders’ deficit of $983,000 in its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026, and, as a result, it was not in compliance with the Stockholders’ Equity Requirement.
The company reported a stockholders' deficit of $983,000 in its Q1 2026 10-Q, failing to meet Nasdaq's minimum $2,500,000 stockholders' equity requirement. This deficiency triggered the delisting determination after the company had briefly regained compliance in February 2026.
Added in current filing · verify on EDGAR →
The Company intends to timely request a hearing before the Panel, at which it will request a suspension of delisting pending its return to compliance. Pursuant to Nasdaq Listing Rule 5815(a) (1) (B), the hearing request will stay the suspension of trading and delisting of the common stock pending the conclusion of the hearing process.
The company will request a hearing before a Nasdaq Hearing Panel to appeal the delisting. Under Nasdaq rules, filing the hearing request will automatically stay the delisting and keep the stock trading on Nasdaq until the panel issues its decision.
Added in current filing · verify on EDGAR →
If the Company’s common stock is delisted from Nasdaq, it could be more difficult to buy or sell the Company’s common stock or to obtain accurate quotations, and the price of the Company’s common stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital and/or trigger defaults and penalties under outstanding agreements or securities of the Company.
The company warns that delisting would make trading more difficult, likely cause material stock price decline, impair capital-raising ability, and potentially trigger defaults or penalties under existing agreements. These are standard but significant risks for investors if the appeal fails.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Item 3.02 — Unregistered Sales of Equity Securities filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Note is convertible into shares of the Company’s common stock at a conversion price of $6.00 per share (subject to adjustment), contingent upon receipt of stockholder approval.
The company issued a convertible note to an accredited investor that can convert into common stock at $6.00 per share, but conversion requires stockholder approval first. The note was sold under Section 4(a)(2) and Rule 506(b) exemptions without general solicitation.
Added in current filing · verify on EDGAR →
The Note was issued in reliance upon the exemption from registration afforded by Section 4(a) (2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated under the Securities Act.
The note was issued as an unregistered private placement to an accredited investor under Regulation D. This means the securities were not registered with the SEC and cannot be freely resold without registration or another exemption.
Event · Item 9.01 — Financial Statements and Exhibits
Item 9.01 — Financial Statements and Exhibits filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
Securities Purchase Agreement, dated May 20, 2026, by and between the Company and DNA Holdings Venture, Inc.
The company entered into a securities purchase agreement with DNA Holdings Venture, Inc. on May 20, 2026. This type of agreement typically involves the sale of company securities to an investor, which may represent a financing transaction or strategic investment.
Added in current filing · verify on EDGAR →
Convertible Promissory Note dated May 26, 2026 issued by the Company to DNA Holdings Venture, Inc.
The company issued a convertible promissory note to DNA Holdings Venture, Inc. on May 26, 2026. This represents debt financing that can convert into equity, potentially diluting existing shareholders when converted, and creates a debt obligation that must be repaid if not converted.
Added in current filing · verify on EDGAR →
Amendment No. 1 to Membership Interest Purchase Agreement, dated May 26, 2026, by and between the Company and DNA Holdings Venture, Inc.
The company and DNA Holdings Venture, Inc. amended an existing membership interest purchase agreement on May 26, 2026. This suggests modification to terms of a prior transaction involving the purchase or sale of membership interests, though the specific changes are not disclosed in this filing.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · May 27, 2026 · How we verify